Table 2 Descriptive statistics of the 245 interventions
No. Interventions (%)Total 245 | ||
|---|---|---|
Patient/disease characteristics | ||
AR-DRGs | Musculoskeletal and connective tissue | 33 (13) |
Mental diseases and disorders | 32 (13) | |
Alcohol or drug use | 29 (12) | |
Circulatory system | 22 (9) | |
Endocrine nutritional and metabolic disorder/disease | 20 (8) | |
Infectious and parasitic diseases | 20 (8) | |
Other | 89 (36) | |
Target Age | Children aged 0 to 14 years | 34 (14) |
Young adults age 14 to 25 years | 5 (2) | |
Working age adults 25 to 65 years | 14 (6) | |
Elderly aged 65+ years | 20 (8) | |
Children and young adults aged 0 to 25 years | 2 (1) | |
Young adults and adults aged 14 to 65 years | 63 (26) | |
Adults and elderly aged 25 to 65 plus years | 92 (38) | |
All | 11 (5) | |
Mixture of the above groups | 4 (2) | |
Target population | Specific | 200 (82) |
General population | 45 (18) | |
Ability to reduce own risk | To some extent | 123 (50) |
No | 122 (50) | |
Condition caused by patients' own behaviour | To some extent | 127 (52) |
No | 118 (48) | |
Intervention details | ||
Type | Medical | 177 (72) |
Lifestyle | 68 (28) | |
Objective | Treatment | 119 (49) |
Prevention | 78 (32) | |
Screening | 33 (14) | |
Diagnosis | 7 (3) | |
Combination | 8 (3) | |
Prevention stage | Primary (completely avert disease) | 78 (32) |
Secondary (slow/halt progression of disease) | 119 (49) | |
Tertiary (limit disability after harm) | 48 (20) | |
Modality | Pharmaceutical | 52 (21) |
Primary medical care or specialist care | 65 (27) | |
Community/media/education | 39 (16) | |
Hospital inpatient | 26 (11) | |
Vaccination | 17 (7) | |
Allied health | 29 (12) | |
Combination of modalities | 9 (4) | |
Other | 8 (3) | |
Nature of publication & study methodology | ||
Year of publication | Median (range) | 2002 (1989 to 2005) |
Strength of evidence | Strong-RCT/meta-analysis | 132 (54) |
Limited | 113 (46) | |
Where published | Peer reviewed journal | 185 (76) |
Government report | 18 (7) | |
Other peer-reviewed report | 26 (11) | |
Other non peer reviewed report | 16 (7) | |
Publication type | General medicine | 52 (21) |
Specialist medicine | 85 (35) | |
Health economics/policy/HTA/public health | 108 (44) | |
Perspective | Health system | 212 (87) |
Societal | 33 (14) | |
Measure of Outcome | Life year | 79 (32) |
QALY | 119 (49) | |
DALY | 46 (19) | |
HYE | 1 (1) | |
Discount rate | 0% | 27 (13) |
3% | 22 (10) | |
5% | 190 (78) | |
Missing | 12 (6) | |
Time horizon of the model in years | Median | 15 |
Interquartile range | 1 to 25 | |
Missing | 89 (36) | |
Duration of benefit in years | Median | 4 |
Interquartile range | 1 to 6 | |
Missing | 81 (33) | |
Downstream costs/savings | Included | 140 (57) |
Quality | ||
Q-Comparator | Appropriate | 215 (88) |
Q-Costs | Appropriate (marginal and clear) | 185 (76) |
Q-Sensitivity analysis | Performed | 239 (98) |
Q-Overall | Met all three requirements above | 173 (71) |
Cost effectiveness | ||
More effective but more costly | 214 (87) | |
Median | $19,017 | |
Interquartile range | $5,997 to $45,670 | |
Dominated | 11 (5) | |
Dominant | 20 (8) | |
Funding & implementation | ||
Funding status | Fully funded | 87 (35) |
Partially funded | 75 (31) | |
Not funded | 83 (34) | |
Patients required to make contribution to costs | Yes | 178 (73) |